INTRODUCTION

- Assessment of Pneumococcal nasopharyngeal carriage prevalence is an important method for monitoring pneumococcal conjugate vaccine (PCV) programs.
- We aimed to measure the prevalence and serotype distribution of pneumococcal carriage in young children from urban and rural Nepal, prior to nationwide introduction of the 10-valent pneumococcal conjugate vaccine (PCV10).

METHODS

- Between April 2014 and April 2015, we recruited children in good health as determined by medical history and clinical judgement of the investigator, from both urban Kathmandu among children age 6-24 months and 25-60 months and from a rural community around Okhaldhunga in 6-24 months old.
- A single nasopharyngeal swab was collected from each child, processed according to WHO guidelines and serotyped by Quellung reaction.
- PCV10 vaccine was introduced in a phase-wise manner starting in the Western development region on 18th January 2015 and reaching the whole country by September 2015.

RESULTS

- Pneumococcal carriage prevalence was 1141/1751 (65%, 95% CI 62.8-67.2%) among children aged 6-24 months in the Urban Group and 500/600 (83.3%, 95% CI 77.4-89.2%) in the Rural Group (p<0.0001).
- The proportion of serotyped pneumococcal isolates that were PCV10 serotypes was significantly higher in the rural group compared with the urban group (p=0.0006).
  - Urban Group (6-24 months): 31.2% (338/1082; 95% CI 28.5-34.1%)
  - Rural Group (6-24 months): 40.7% (178/437; 95% CI 36.1-45.5%)

CONCLUSION

- Rural Nepalese children have higher pneumococcal carriage prevalence and greater proportion of PCV10 serotypes in nasopharyngeal specimens than their urban counterparts.
- There is a substantial carriage and vaccine type carriage so there is ample opportunity to monitor the impact of the PCV program on the community circulation of pneumococcal strains.

Figure 1. Serotype-specific pneumococcal carriage distribution in urban and rural Nepalese children prior to PCV10 introduction.

Figure 2. Odds ratios with 95% CIs of serotypes that were significantly more likely (serotypes 1, 14, and 18B) or less likely (serotype 34) to be detected in the rural cohort.

Funding

This work is made possible with support from Gavi, the Vaccine Alliance.